Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Purchases $46,750.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $1.87 per share, with a total value of $46,750.00. Following the acquisition, the director now directly owns 1,130,060 shares of the company’s stock, valued at $2,113,212.20. This trade represents a 2.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA opened at $2.00 on Monday. MAIA Biotechnology, Inc. has a 52-week low of $0.85 and a 52-week high of $5.99. The stock has a market cap of $50.66 million, a price-to-earnings ratio of -1.45 and a beta of 0.14.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.21. Equities research analysts predict that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.

Hedge Funds Weigh In On MAIA Biotechnology

Several large investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new position in shares of MAIA Biotechnology in the third quarter valued at about $31,000. Ground Swell Capital LLC purchased a new position in shares of MAIA Biotechnology in the second quarter valued at about $56,000. Finally, Geode Capital Management LLC lifted its position in shares of MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after acquiring an additional 35,821 shares in the last quarter. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.